View Item 

Show simple item record

Hypersensitivity to inhaled TOBI ® following reaction to gentamicin
dc.contributor.authorSpigarelli, Michael G.en_US
dc.contributor.authorHurwitz, Martin E.en_US
dc.contributor.authorNasr, Samya Z.en_US
dc.date.accessioned2006-04-19T14:23:27Z
dc.date.available2006-04-19T14:23:27Z
dc.date.issued2002-04en_US
dc.identifier.citationSpigarelli, Michael G.; Hurwitz, Martin E.; Nasr, Samya Z. (2002)."Hypersensitivity to inhaled TOBI ® following reaction to gentamicin." Pediatric Pulmonology 33(4): 311-314. <http://hdl.handle.net/2027.42/35320>en_US
dc.identifier.issn8755-6863en_US
dc.identifier.issn1099-0496en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/35320
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=11921461&dopt=citationen_US
dc.description.abstractCystic fibrosis (CF) is the most common autosomal-recessive disease in Caucasians. Colonization with Pseudomonas aeruginosa ( P. aeruginosa ) of the CF airways causes deterioration of pulmonary status. TOBI ® (Tobramycin solution for inhalation) is an inhaled antibiotic that can improve the pulmonary disease. We report on a 9-year old boy with CF who developed a rash following a course of IV gentamicin. The rash resolved after its discontinuation. However, the rash returned all over his body, with the start of inhalation of TOBI ® therapy. We desensitized the patient using escalating doses of inhaled TOBI ® . He tolerated the procedure well, and continues to be on TOBI ® 9 months after desensitization on a once-a-day regimen. Pediatr Pulmonol. 2002; 33:311-314. © 2002 Wiley-Liss, Inc.en_US
dc.format.extent113823 bytes
dc.format.extent3118 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.language.isoen_US
dc.publisherWiley Subscription Services, Inc., A Wiley Companyen_US
dc.subject.otherLife and Medical Sciencesen_US
dc.subject.otherMiscellaneous Medicalen_US
dc.titleHypersensitivity to inhaled TOBI ® following reaction to gentamicinen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPediatricsen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDivision of Pediatric Pulmonary Medicine, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center. Ann Arbor, Michiganen_US
dc.contributor.affiliationumDivision of Pediatric Pulmonary Medicine, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center. Ann Arbor, Michiganen_US
dc.contributor.affiliationumDivision of Pediatric Pulmonary Medicine, Department of Pediatrics and Communicable Diseases, University of Michigan Medical Center. Ann Arbor, Michigan ; Department of Pediatrics, University of Michigan Medical Center, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0212.en_US
dc.identifier.pmid11921461en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/35320/1/10049_ftp.pdfen_US
dc.identifier.doihttp://dx.doi.org/10.1002/ppul.10049en_US
dc.identifier.sourcePediatric Pulmonologyen_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
10049_ftp.pdf
Size:
111.1KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.